For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors, steroids, combination therapies, etc.
Scope of the Report:
This report studies the COPD Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the COPD Drugs market by product type and applications/end industries.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
The bronchodilators segment is one of the fastest growing segments of the COPD drugs market. Bronchodilators help relax bronchial muscles resulting in normal breathing. These drugs can be categorized into three types, namely beta-sympathomimetic, anticholinergics, and xanthine derivatives.
The global COPD Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of COPD Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Abbott Laboratories
- Boehringer Ingelheim
- Roche Holding AG
- Teva Pharmaceutical Industries
- Vectura Group
- Mylan NV
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- PDE-4 Inhibitors
- Combination Therapies
Market Segment by Applications, can be divided into